Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00412620
Status:
TERMINATED
Last Update Posted:
2011-04-27
First Post:
2006-12-14
Brief Title:
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
Double-blind Randomized Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
Status:
TERMINATED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR Diagnostic and Statistical Manual of Medical Disorders Fourth Edition Text Revision criteria for an acute exacerbation of schizophrenia or schizoaffective disorder
Detailed Description:
To explore the safety and efficacy of ABT-925 treatment at three different doses for 6 weeks compared with placebo in subjects with a diagnosis of acute exacerbation of schizophrenia or schizoaffective disorder according to DSM-IV-TR criteria Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None